Recursion Insider Buying Surge Signals Potential Upside Amid Current Low
Insider buy by Recursion board member Dar Zavain signals confidence in the AI‑drug platform; watch for pipeline milestones that could lift the stock.
3 minutes to read
RECURSION PHARMACEUTICALS